These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20051811)

  • 21. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
    Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
    Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine and docetaxel combination for the treatment of breast cancer.
    Morishita M; Leonard RC
    Womens Health (Lond); 2008 Jan; 4():11-22. PubMed ID: 19072447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
    Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM
    Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
    Verma S; Wong NS; Trudeau M; Joy A; Mackey J; Dranitsaris G; Clemons M
    Am J Clin Oncol; 2007 Jun; 30(3):297-302. PubMed ID: 17551309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis.
    Jiang Z; Yang Y; Li L; Yue Z; Lan L; Pan Z
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S957-S963. PubMed ID: 30539829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
    Semiglazova TIu; Gershanovich ML
    Vopr Onkol; 2001; 47(3):298-302. PubMed ID: 11544827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
    Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
    PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
    Wist EA; Sommer HH; Ostenstad B; Risberg T; Bremnes Y; Mjaaland I
    Acta Oncol; 2004; 43(2):186-9. PubMed ID: 15163168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
    Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
    Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
    Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine plus docetaxel combination therapy.
    Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
    Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
    Schwartzberg LS; Cobb P; Walker MS; Stepanski EJ; Houts AC
    Support Care Cancer; 2009 Aug; 17(8):1081-8. PubMed ID: 19148686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
    Pajk B; Cufer T; Canney P; Ellis P; Cameron D; Blot E; Vermorken J; Coleman R; Marreaud S; Bogaerts J; Basaran G; Piccart M
    Breast; 2008 Apr; 17(2):180-5. PubMed ID: 17976988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
    Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
    Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
    Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
    Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
    Seidman AD; O'Shaughnessy J; Misset JL
    Oncologist; 2002; 7 Suppl 6():20-8. PubMed ID: 12454316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
    Best JH; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.